Oncostatin M protein
3x Oncostatin M protein found in fitzgerald
- Antibody SubtypeRecombinant Proteins
- Area of researchCytokines & Growth Factors
- Type of proteinRecombinant
- Expression SystemEscherichia coli
- Grade & PurityGrater than 98% pure
- Shipping conditionsBlue Ice
- Gene target
- Short nameOncostatin M protein
- Alternative nameOncostatin M protein
30R-AO009 | Oncostatin M proteinsize: 10 µg | 400.74 USD
- Catalog number30R-AO009
- Price400.74 USD
- Size10 µg
- ResiduesRegion of Oncostatin M protein corresponding to amino acids MAAIGSCSKE YRVLLGQLQK QTDLMQDTSR LLDPYIRIQG LDVPKLREHC RERPGAFPSE ETLRGLGRRG FLQTLNATLG CVLHRLADLE QRLPKAQDLE RSGLNIEDLE KLQMARPNIL GLRNNIYCMA QLLDNSDTAE PTKAGRGASQ PPTPTPASDA FQRKLEGCRF LHGYHRFMHS VGRVFSKWGE SPNRSRRHSP HQALRKGVRR.
- Form & BufferProvided as a lyophilized powder.
- StorageStore at 4 deg C until reconstitution. Following reconstitution aliquot and freeze at -20 deg C for long term storage. Avoid repeated freeze/thaw cycles.
- Tested forPlease refer to the datasheet
- BioactivityThe ED50 was determined by the dose-dependent stimulation of the proliferation of human TF-1 cells is approximately 2.0 ng/ml, corresponding to a specific activity of approximately 5 x 10^5 units/mg.
- ConceptRegistry number:106956-32-5Scope note:A cytokine with both pro- and anti-inflammatory actions that depend upon the cellular microenvironment. Oncostatin M is a 28 kDa monomeric glycoprotein that is similar in structure to LEUKEMIA INHIBITORY FACTOR. Its name derives from the the observation that it inhibited the growth of tumor cells and augmented the growth of normal fibroblasts.CASN1 number:Oncostatin M
- Tree numbers
- Qualifiersimmunology, pharmacokinetics, biosynthesis, physiology, therapeutic use, secretion, toxicity, poisoning, administration & dosage, adverse effects, agonists, blood, cerebrospinal fluid, chemical synthesis, contraindications, deficiency, chemistry, drug effects, urine, radiation effects, history, analysis, antagonists & inhibitors, classification, economics, genetics, isolation & purification, metabolism, pharmacology, standards, supply & distribution, ultrastructure
- PubMedsOSMR is able to bind OSM and interleukin-31 when associated to soluble gp130 or soluble interleukin-31R, respectively, and to neutralize both cytokine propertiesFPLCA has been mapped to 5p13.1-q11.2, and by candidate gene analysis, study identified missense mutations in the OSMR gene, encoding oncostatin M-specific receptor beta (OSMRbeta), in three families.study provides evidence for the existence of a novel pathogenic mutation in the OSMR gene in a caucasian family with familial primary cutaneous amyloidosisAn alternatively spliced variant of OSMR transcribing a soluble form of this receptor has been characterized in esophageal squamous cell carcinoma.This study identified a new heterozygous OSMR missense mutation in primary localized cutaneous amyloidosis.this study offers new findings on the molecular genetics and disease relevance of mutations in OSMR in Familial primary localized cutaneous amyloidosis.
- Gene ontology - Biological process
- Gene ontology - Cellular component
- Gene ontology - Molecular function
- Entrez Gene
30R-AO002 | Oncostatin M proteinsize: 10 µg | 400.74 USD
30R-2605 | Oncostatin M proteinsize: 10 µg | 431.38 USD